>
Organization
Basis PFS A/S
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed

News on Basis PFS A/S

... primary endpoint. The trial demonstrated a statistically significant improvement in progression-free survival (PFS) of ADCETRIS (brentuximab vedotin) in combination with CHP (cyclophosphamide, doxorubicin, prednisone) versus ...
... to VIZIMPRO (n=227) or gefitinib (n=225). The primary endpoint was progression-free survival (PFS) as determined by blinded Independent Radiologic Central (IRC) review, and additional efficacy ...
... Alecensa significantly reduced the risk of disease worsening or death (progression-free survival, PFS) by 47 percent (HR=0.53, 95 percent CI: 0.38, 0.73, p The study ...
... (alectinib) significantly reduced the risk of disease worsening or death (progression-free survival, PFS) by more than half (53 percent) compared to crizotinib when given as ...
... treatment showed that patients lived significantly longer without disease worsening (progression-free survival, PFS) compared to crizotinib in the ALEX Study, a global phase III study ...
... study demonstrates that treatment with GAZYVA plus bendamustine results in progression-free survival (PFS) for a median of 29.2 months compared to bendamustine alone with a ...
Subscribe now for full coverage on Basis PFS A/S
Start My Free Trial